Skip to content

Quick ratio at other companies

Opko Health logo
Opko HealthOPK
3.2×+0.9×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
4.9×+2.3×
AMP
Amphastar PharmaceuticalsAMPH
2.8×+0.8×
Theravance Biopharma logo
Theravance BiopharmaTBPH
13.1×+8.4×
HRO
HarrowHROW
2.3×+1.4×
Precigen logo
PrecigenPGEN
4.1×+0.6×

Other financials

Income statement

See full
Revenue$58.3M+104%
Gross profit$46.3M+86.8%
Operating income-$15.5M+80.4%
Net income-$30.4M+67.8%
EPS (diluted)-$0.37+71.8%

Balance sheet

See full
Cash & equivalents$180.9M-14.8%
Total debt$166.3M-18.3%
Total equity-$337.0M+0.4%
Total assets$305.1M+3.7%

Cash flow

See full
Operating cash flow-$15.6M+81.6%
CapEx$61.0K+239%
Free cash flow-$15.7M+81.5%

Valuation

See full
Market cap$846.21M+13.4%
Enterprise value$831.61M+12.7%
P/S4.1×-5.0×

Profitability

See full
Gross margin84.9%-1.3pp
Operating margin-47.1%-21.9pp
Net margin-76.8%-34.5pp
FCF margin-47.7%-22.1pp

Returns & leverage

See full
Return on equity-147.9%
Debt / equity5.6×
Current ratio2.2×-1.4×

Where this comes from

Calculated from Phathom Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phathom Pharmaceuticals, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Phathom Pharmaceuticals, Inc.'s quick ratio?
Phathom Pharmaceuticals, Inc. (PHAT) reported quick ratio of 2.1× in Q1 2026.
How has Phathom Pharmaceuticals, Inc.'s quick ratio changed year-over-year?
Phathom Pharmaceuticals, Inc.'s quick ratio decreased by 37.0% year-over-year, from 3.3× to 2.1×.
What is the long-term trend for Phathom Pharmaceuticals, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Phathom Pharmaceuticals, Inc.'s quick ratio has grown at a -21.4% compound annual growth rate (CAGR), from 5.2× to 1.6×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.